CPG 7909 Injection in Non-Small Cell Lung Cancer
NCT00070629
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: Office of Ronald Yanagihara, Gilroy, California +23 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00033410
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tirapazamine may make the tumor cells more sensitive to radiation therapy. Combining chemotherapy, radiation therapy, and tirapazamine may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with tirapazamine and radiation therapy in treating patients who have stage... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2009
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +1 locations
Conditions: Lung Cancer
Register for Updates
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
NCT00174434
Completed
This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/26/2009
Locations: Pfizer Investigational Site, Harvey, Illinois +5 locations
Conditions: Breast Neoplasms
Register for Updates
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
NCT00049790
Completed
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2009
Locations: Indiana Cancer Pavilion, Indiana University, Indianapolis, Indiana
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
Completed
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2008
Locations: NEA Clinic, Jonesboro, Arkansas +18 locations
Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Register for Updates
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
NCT00378313
Completed
The primary purpose of this study is to determine whether locally advanced breast cancer responds (by shrinking, by not progressing or by being destroyed) to combined chemotherapy (gemcitabine, epirubicin and paclitaxel) given before surgery to patients with locally advanced breast cancer. This study will also evaluate the toxicity of the chemotherapy combination to patients and will determine survival and progression-free survival 2 years after treatment. Also, the study will look at whether th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/24/2008
Locations: NSABP Foundation, Inc., Pittsburgh, Pennsylvania
Conditions: Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Locally Advanced
Register for Updates
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
NCT00569751
Completed
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2008
Locations: Scottsdale Healthcare, Scottsdale, Arizona +52 locations
Conditions: Cardiovascular Disease, de Novo Coronary Lesions
Register for Updates
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: California Cancer Care, Greenbrae, California +16 locations
Conditions: Ovarian Neoplasm
Register for Updates
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
NCT00161278
Terminated
Patients who are at least 18 years of age and have a type of cancer known as advanced non-small cell lung cancer may be eligible for this study if they meet all of the inclusion/exclusion criteria. Background: The standard treatment for patients with advanced non-small cell cancer is chemotherapy. The two drug combination, carboplatin (Paraplatin) and paclitaxel (Taxol), is commonly used as the first treatment. Unfortunately, standard treatment with chemotherapy only shrinks the cancer in about... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2008
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis
NCT00055133
Completed
Paxceed™ is being developed by Angiotech Pharmaceuticals, Inc. for the treatment of Rheumatoid Arthritis (RA). The main objective of this study is to determine the effectiveness of treatment with Paxceed™ in patients with RA. In RA, there is an increase in cell growth and changes in cell function. The active substance in Paxceed™, paclitaxel, has undergone clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an agent that stops growth of cells and blocks cer... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
07/26/2008
Locations: University of Alabama at Birmingham, Birmingham, Alabama +8 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
NCT00003327
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or refractory head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: California Cancer Center, Fresno, California +19 locations
Conditions: Head and Neck Cancer
Register for Updates
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
NCT00024414
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Arizona Oncology Associates, Tucson, Arizona +7 locations
Conditions: Prostate Cancer
Register for Updates